<DOC>
	<DOC>NCT01119768</DOC>
	<brief_summary>To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.</brief_summary>
	<brief_title>Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients</brief_title>
	<detailed_description>A multicenter, randomized, open-label Phase IV study exploring symptom control rate in co-diagnosed NERD and chronic gastritis patients treated with 8 weeks esomeprazole treatment regimen and 2 weeks esomeprazole treatment regimen.</detailed_description>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Gastritis, Atrophic</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Heartburn and/or regurgitation symptoms last for at least 3 months Endoscopic diagnosed as chronic gastritis (nonatrophic, and mild atrophic gastritis) within 2 weeks prior to randomization GerdQ score =8 Endoscopic visible reflux esophagitis, esophageal varices, Barrett's esophagus, malignancy or peptic ulcer Patients with Hp positive result and are eager to take Hp eradication therapy will be excluded If Hp positive, patients could take Hp eradication therapy after the study completion Previous PPI or H2RA therapy in the last 2 weeks before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>GI</keyword>
	<keyword>Nexium</keyword>
	<keyword>Phase IV</keyword>
	<keyword>Co-diagnosed NERD</keyword>
</DOC>